22-09-2011: Rondol capital increase boosts sales in pharma and high tech industries
http://www.rondol.com/
Due to a better organization and efficiency of the sales team, Rondol sales have progressed rapidly with an average monthly order intake around £200K since September 2010 vs. £70K in average over the previous 18 months.
The Rondol board has therefore decided to implement a further capital increase (£300k) in order to support further marketing investments in the pharma sector as well as the establishment of a technical office in Continental Europe.
The capital increase was completed in August. Marzac Investment contributed 83% to this capital increase and now owns 39.8% of the company.
Victoire de Margerie, Founder & CEO of Marzac Investment states: "Rondol is a good example of the three missions of the Marzac fund: create sustainable financial value, bring technology from art to industry and promote industrial entrepreneurship for the new generation - half of Rondol's staff are now 30 years of age or younger and they come from 6 different nationalities."
Gérard Tardy, former CEO of Schröders Capital, board member of several medtech and healthcare companies and private investor in Rondol states: "Rondol has made great progress with first class industrial customers, especially in Germany and the US."